The Intricate Interplay between the ZNF217 Oncogene and Epigenetic Processes Shapes Tumor Progression

Area of Science:

• Oncology
• Epigenetics
• Molecular Biology

Background:

• The oncogenic transcription factor ZNF217 is implicated in cancer progression, drug resistance, and cell plasticity.
• ZNF217 expression levels serve as a biomarker for poor prognosis and predict response to anticancer therapies.
• The interplay between ZNF217 and epigenetic regulation in cancer remains incompletely understood.

Purpose of the Study:

• To review recent advances in understanding the collaboration between ZNF217 and epigenetic processes in oncogenesis.
• To explore how ZNF217 influences cancer cell signaling and hallmark capabilities.
• To discuss potential translational medicine and therapeutic strategies targeting ZNF217-epigenetic interactions.

Main Methods:

• Literature review of studies investigating ZNF217 function in cancer.
• Analysis of molecular mechanisms linking ZNF217 to DNA methylation, noncoding RNAs, and epitranscriptome.
• Synthesis of findings on ZNF217's role in tumor progression and therapeutic resistance.

Main Results:

• ZNF217 reprogramming of cellular circuits drives hallmark cancer capabilities.
• Aberrant ZNF217 expression may result from DNA methylation changes at its locus or cross-talk with noncoding RNAs.
• ZNF217 protein modulates gene expression by influencing DNA methylation, noncoding RNAs, and the epitranscriptome.

Conclusions:

• ZNF217 collaborates with epigenetic mechanisms to orchestrate oncogenesis.
• Targeting the ZNF217-epigenetic axis presents promising therapeutic avenues.
• Further research into these interactions can advance cancer treatment strategies.